2型糖尿病，这一全球性流行病，正悄然影响着近5亿成年人的健康，带来沉重的疾病负担。近年来，科学家们不断探索2型糖尿病与肿瘤之间的复杂 ...

恩格列净，一种钠-葡萄糖协同转运蛋-2（SGLT-2）抑制剂，在EMPA-KIDNEY试验中显示出对患有慢性肾脏病（CKD）且有疾病进展风险的受试者具有积极的心肾效应。为测试受试者停止服用恩格列净后效果如何，因停药后可能会出现额外的益处或危害。研究者 ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

格隆汇3月17日丨赛升药业(300485.SZ)公布，公司子公司北京赛而生物药业有限公司(简称“赛而生物”)近日收到了国家药品监督管理局下发的达格列净片境内生产药品注册上市许可申请的《受理通知书》。

与此同时，维生素 D 缺乏在人群中也较为普遍，即使在阳光充足的马来西亚也不例外。越来越多的证据表明，OSA 与维生素 D 缺乏之间存在着双向关联。此外，钠 - 葡萄糖协同转运蛋白 2 抑制剂（Sodium glucose transporter-2 inhibitor，SGLT2i）作为一种新型口服降糖药，除了能降低血糖外，还具有心血管保护作用。但目前关于维生素 D 补充剂以及 SGLT2i 在 ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

The biggest advantage of the drug going off patent is that the prices will plummet. The patented medicine, sold as Jardiance, ...

Type 2 diabetes is a global health challenge affecting more than 400 million adults. While it is often seen as a lifelong ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

MONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) ...